The joint venture aims to address unmet needs in the treatment of mood and anxiety disorders through novel neuroplastogens.

In the Phase IIIa FRONTIER 2 trial, participants aged 12 years and older administered Mim8 showed significant and superior ...

Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how ...

In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Melissa Lattanzi, VP, Emerging Therapies, Cencora ...

With competition for follow-on-biologics on the upswing—and a potential market boom perhaps around the corner—continued ...

Study findings indicated that psilocybin can reduce the symptoms of depression, with response and remission rates showing ...

It’s long past time for the industry to fully embrace the digital age. It’s fine to keep paper back-ups of data, but using ...

From Big Pharma to biotech—and a globe-spanning journey along the way—Yvonne Greenstreet, this year’s Healthcare ...

Respondents said they were concerned about their own mental health or the mental health of another person at higher rates ...

The National Institute for Public Employee Healthcare Policy attributed the importance to the rising cost of health care.

For decades, one of the main priorities of the United States healthcare system has been to develop life-saving treatments for ...

As of the writing of this column (May 1), the XBI stood at $88.30, well off of its recent recovery high of $102+ on Feb. 27, ...